AstraZeneca: new positive CHMP opinion for Tagrisso
(CercleFinance.com) - On Monday AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency had issued a positive opinion with a view to extending the indication for Tagrisso, its lung cancer tablet.
The pharmaceutical group points out that the CHMP recommended approval of Tagrisso in the European Union for the treatment of inoperable non-small-cell lung cancer presenting an EGFR mutation with deletions of exon 19 or L858R mutation of exon 21.
This positive opinion concerns patients whose disease has not progressed during or following chemotherapy treatment.
The Group states that this recommendation is based on the initial results of a phase III study currently being conducted in 216 participants.
Tagrisso is currently approved in around 100 markets, including the United States, Europe, China and Japan, mainly in the first-line treatment of advanced or metastatic EGFR-mutated lung cancer.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The pharmaceutical group points out that the CHMP recommended approval of Tagrisso in the European Union for the treatment of inoperable non-small-cell lung cancer presenting an EGFR mutation with deletions of exon 19 or L858R mutation of exon 21.
This positive opinion concerns patients whose disease has not progressed during or following chemotherapy treatment.
The Group states that this recommendation is based on the initial results of a phase III study currently being conducted in 216 participants.
Tagrisso is currently approved in around 100 markets, including the United States, Europe, China and Japan, mainly in the first-line treatment of advanced or metastatic EGFR-mutated lung cancer.
Copyright (c) 2024 CercleFinance.com. All rights reserved.